Fig. 7

ADV-ApoA1 inhibits TNBC metastasis in mouse models. (a) Treatment scheme of the 4T1-luciferase orthotopic breast cancer model. (b) Monitoring of tumor metastasis using bioluminescence analysis. (c) mRNA level of KRT14 in tissue from the 4T1-luciferase orthotopic breast cancer model, assayed by qPCR. (d) mRNA levels of KRT14 and EMT-associated genes in tissue from the 4T1-luciferase orthotopic breast cancer model, assayed by qPCR. (e) Expression of p-IκB, p65, and KRT14 in 4T1 metastatic tumors of mice that was treated with PBS, ADV-Ctr, or ADV-ApoA1 in orthotopic tumors. (f) Treatment scheme of the MDA-MB-231 orthotopic breast cancer model in nude mice. (g) Mice sacrificed on day 20 after the first oncolytic virus treatment, lung tissue collected and used for H&E staining. The number of metastatic nodes was calculated. (h) Survival curve of mice treated with oncolytic virus. (i) Treatment scheme of the MMTV-PyMT mice. (j) Mice sacrificed three weeks after the first virus injection, lung tissue sections were collected and used for H&E staining. The number of metastatic nodes was calculated. ns: no significant difference; *p < 0.05; **p < 0.01